Just two weeks ago, Intercept CMO Jason Campagna followed the biotech’s founding CEO out the door to pursue other opportunities, per an SEC filing, as analysts sense a major shift taking place at the company. Now, that new opportunity has come to light.
Campagna is taking the same CMO position at Q32 Bio, the company announced Tuesday morning, joining CEO Mike Broxson’s team in Cambridge, MA as they explore the next generation of complement drugs. The move comes after Q32 pulled in two fundraising rounds in 2020 totaling more than $100 million and as the biotech is in IND-enabling studies for its lead program, dubbed ADX-097.
Campagna wouldn’t comment on the speculation around Intercept’s inner-workings or future. Through a Q32 spokesperson, Campagna preemptively declined comment Tuesday on all matters related…